Analysts Boost Profit Forecasts On Two Names. One Is A Data Center Play.

This data center parts provider hit an all-time high on Monday. And a biotech stock is building a base.

Investors Business Daily • 15 hours ago

Harrow (HROW) Reports Next Week: Wall Street Expects Earnings Growth

Harrow (HROW) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research • Feb 23, 2026

Harrow To Report Fourth Quarter and Year-End 2025 Financial Results After Market Close on March 2, 2026

NASHVILLE, Tenn., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it will report its financial results for the fourth quarter and year ended December 31, 2025, on Monday, March 2, 2026, after the market close.

GlobeNewsWire • Feb 18, 2026

Harrow Announces Cash-Pay Direct-to-Prescriber PharmaPack™ Kits

NASHVILLE, Tenn., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced the launch of a new Direct-to-Prescriber (DTP) cash-pay offering called PharmaPack, which expands the Company's commitment to offering affordable FDA-approved branded products as alternatives to off-label compounded formulations.

GlobeNewsWire • Feb 17, 2026

Eye Care Stock Sees New Path After Guidance

This eye care products maker reaffirmed its revenue guidance, kicking off a two-day stock rally. Shares are now testing a key moving average.

Investors Business Daily • Feb 4, 2026

Strength Seen in Harrow (HROW): Can Its 9.7% Jump Turn into More Strength?

Harrow (HROW) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Zacks Investment Research • Feb 3, 2026

Harrow Reaffirms 2025 Full-Year Revenue Guidance of $270–$280 Million, Marking Another Year of Strong Growth

Doubling of VEVYE® Sales Force is On Track, Expansion of IHEEZO® Commercial Footprint to  the Office-Based Setting Underway, and Doubling TRIESENCE® Commercial Footprint in the Surgical-Based Setting is Proceeding

GlobeNewsWire • Feb 2, 2026

Harrow: Revisiting This Eyecare Growth Story Ahead Of Q4 Update

Harrow, Inc. continues to execute on its branded ophthalmic portfolio, with Vevye and Iheezo outperforming expectations and gaining market share. Despite a slight Q3 revenue miss and lowered 2025 guidance ($270M–$280M), operating leverage and commercial expansion underpin a robust growth outlook. Vevye's preferred formulary status and expanded coverage in 2026, alongside Iheezo's strong adoption, set up for accelerating revenue and margin improvement.

Seeking Alpha • Jan 22, 2026

Harrow: Flirting With Missing 2025 Revised Guidance

Harrow may deliver $265M in 2025 revenue, potentially missing the low end of its revised $270M–$280M guidance. Recent Bloomberg data suggest strong growth in Iheezo and Vevye, but specialty and compounded segments face headwinds and one-time impacts. Considerable uncertainty exists due to data limitations and ASP uncertainty.

Seeking Alpha • Jan 12, 2026

Eye Drops Maker Sets Up After Strategic Buy; Sales Outlook Strong

Biotech stock Harrow is in a cup base with a buy point of 50.72 after third-quarter results.

Investors Business Daily • Dec 9, 2025